Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The facility sets a new benchmark in respiratory diagnostics
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Subscribe To Our Newsletter & Stay Updated
